Breaking Barriers: Advances of MRNA in Africa
Discussion on how advances in mRNA vaccines can help bridge a barrier in vaccine inequity in Africa
5/12/20261 min read
Featuring Dr. Ernest A. Wandera, a senior scientist at KEMRI’s Center of Virus Research, the session brought together stakeholders from the RNA Society, RNA Salon Kenya, and Lexogen to address a critical vulnerability: the fact that Africa currently produces less than 1% of the vaccines it administers. A primary talking point would have been the shift from a "fill and finish" model to the "hub-and-spoke" technology transfer initiative, which aims to empower regional hubs like Kenya to manufacture their own biological countermeasures.
A significant portion of the discussion focused on the scientific advantages that mRNA platforms offer over traditional vaccine methods. Unlike traditional techniques that require growing pathogens in large-scale bioreactors, mRNA vaccines are "programmable," utilizing genetic code to teach the body to recognize specific viral proteins. This technology allows researchers to move from identifying a viral sequence to starting clinical trials in a matter of weeks rather than years. Such versatility is vital for addressing Africa's unique disease burden, including neglected tropical diseases and endemic threats like malaria, tuberculosis, and rotavirus.
Addressed was the specific technical and logistical hurdles faced within the African continent. Key talking points included the "cold chain" challenge, where early mRNA vaccines required ultra-low temperatures (-70°C) that are difficult to maintain in rural or resource-constrained settings. The webinar explored emerging innovations in thermostability, such as lyophilized (freeze-dried) formulations that can be stored at ambient temperatures. There was shared insights into the WHO-led mRNA Technology Transfer Programme, emphasizing that overcoming these barriers requires not just equipment, but a sustained investment in local workforce training and specialized biosafety infrastructure.
The webinar concluded with a forward-looking roadmap for achieving the African Union’s goal of producing 60% of the continent’s vaccines locally by 2040. This future vision involves the establishment of smart vaccine facilities in locations like Konza Technopolis, capable of full-cycle research, development, and mass production. By fostering a local RNA research ecosystem through organizations like RNA Salon Kenya, the seminar positioned mRNA technology as the cornerstone for a new Public Health Order in Africa, where health security is driven by local innovation rather than international donation.